On the basis of the above observations, we concluded that downregulating the expression of AMPKα1 could significantly inhibit tumor growth in subcutaneous cell-line-derived xenograft model and patient-derived xenograft model, which highly suggests the potential of AMPKα1 gene silencing as a therapeutic target for CRC treatment. Here, PRKAA1 is linked to colorectal carcinoma.